Cue Biopharma Inc. (CUE)
NASDAQ: CUE
· Real-Time Price · USD
0.82
0.03 (3.80%)
At close: Aug 15, 2025, 9:55 AM
3.80% (1D)
Bid | 0.82 |
Market Cap | 63.01M |
Revenue (ttm) | 7.99M |
Net Income (ttm) | -40.58M |
EPS (ttm) | -0.51 |
PE Ratio (ttm) | -1.61 |
Forward PE | -1.48 |
Analyst | Buy |
Ask | 0.84 |
Volume | 35,846 |
Avg. Volume (20D) | 322,696 |
Open | 0.81 |
Previous Close | 0.79 |
Day's Range | 0.79 - 0.83 |
52-Week Range | 0.45 - 1.99 |
Beta | 1.53 |
Analyst Forecast
According to 0 analyst ratings, the average rating for CUE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Cue Biopharma has released their quartely earnings
on Aug 12, 2025:
Next Earnings Release
Cue Biopharma Inc. is scheduled to release its earnings on
Nov 13, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-1.45%
Cue Biopharma shares are trading higher after the ...
Unlock content with
Pro Subscription
1 month ago
+8.67%
Cue Biopharma shares are trading higher after the company announced it received FDA pre-IND feedback for CUE-401 autoimmune therapy.